Navigation Links
A rocking good lecture
Date:3/3/2010

A University academic who left school early with dreams of being a rock star has been recognised for his internationally outstanding work in microbiology and his studies into the social lifestyle of the opportunistic bacterium Pseudomonas aeruginosa the leading cause of death in Cystic Fibrosis patients and an important cause of hospital acquired infections.

Dr Steve Diggle, Royal Society University Research Fellow (and part-time bass guitarist) at The University of Nottingham, has been awarded a prize lecture by the Society for General Microbiology for outstanding research by a microbiologist in the early stages of his career.

Steve, who has spent over a decade working on bacterial cell-to-cell communication quorum sensing will give the Fleming Lecture at this year's Society for General Microbiology (SGM) Spring 2010 Meeting in Edinburgh on March 30.

Dr Diggle's research focuses on the ability of pathogenic bacteria to coordinate cooperative behaviours to exploit their hosts. His lecture, 'Microbial communication and virulence: lessons from evolutionary theory', addresses questions such as; what factors influence cooperation and the evolution of virulence in microbes; and can we exploit these to develop new antimicrobial strategies?

Steve said: "It is an honour, privilege and somewhat of a surprise to be given this award by the SGM. I am delighted that the Society has shown interest in my research and I hope that by furthering our understanding of the evolution of virulence in pathogenic organisms, we will find novel ways to combat the diseases they cause. This award would not have come about without the support of a number of my excellent colleagues and collaborators and so I extend my thanks to them."

In 2006 Steve received a five year fellowship from the Royal Society and decided to stay at The University of Nottingham to continue on his research into the evolutionary implications of quorum sensing, looking at why this type of behaviour occurs and is maintained within populations of pathogenic bacteria. His research has been published in the journals Nature and Current Biology.


'/>"/>

Contact: Lindsay Brooke
lindsay.brooke@nottingham.ac.uk
44-115-951-5751
University of Nottingham
Source:Eurekalert

Related biology news :

1. Nobel Laureate Roger Tsien to present national lecture at the Biophysical Society meeting
2. Nobel laureate claims the 2010 Herbert Tabor Lectureship
3. Plenary lecturers share science and policy perspectives
4. Evolution of hyperactivity is focus of free public lecture at UC Riverside
5. Vertical farming advocate to be featured at upcoming free lecture at NJIT
6. Distinctive Voices@The Beckman Center announces fall lecture series
7. Public lecture at UC Riverside to discuss origin and fate of universe
8. Woods Hole lecture series explores range of scientific topics
9. MIT: Jeremy Nathans to deliver Scolnick Prize lecture
10. Annual Michael & Susan Dell lectureship in child health
11. AIUM presents 2009 William J. Fry Memorial Lecture award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... January 11, 2017 , ... ... Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against ... previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
(Date:1/11/2017)... ... 11, 2017 , ... Symbios Technologies, Inc., a ... Science Foundation (NSF) has awarded Symbios a Small Business Innovation Research (SBIR) ... the Symbios Tubular Plasma Reactor™ (TPR™) by scaling the system for first customer ...
(Date:1/11/2017)... 11, 2017  GenVec, Inc. (NASDAQ: ... today that its chief scientific officer, Douglas ...  "AdenoVerse™ platform for translational development of innovative gene ... the upcoming Phacilitate Cell & Gene Therapy World ... Florida.  Dr. Brough,s presentation will highlight the utility ...
Breaking Biology Technology: